Article
Gastroenterology & Hepatology
Simon Kurt, Benedicte Caron, Celia Gouynou, Patrick Netter, Carolynne J. Vaizey, StevenD. Wexner, Silvio Danese, Cedric Baumann, Laurent Peyrin-Biroulet
Summary: This study aimed to describe the prevalence of FI in patients with IBD using an available scoring system and identify associated risk factors. The results showed that approximately one fifth of IBD patients in this real-world cohort reported FI. Increased age, diarrhea, stool consistency according to the Bristol stool chart, and abdominal pain were associated with FI.
DIGESTIVE AND LIVER DISEASE
(2022)
Article
Gastroenterology & Hepatology
Andreas Zollner, Andreas Schmiderer, Simon J. Reider, Georg Oberhuber, Alexandra Pfister, Bernhard Texler, Christina Watschinger, Robert Koch, Maria Effenberger, Tim Raine, Herbert Tilg, Alexander R. Moschen
Summary: This study demonstrated the diagnostic equivalence of FLCN2 and FCAL in inflammatory bowel diseases, with both biomarkers showing comparable sensitivity and specificity. Furthermore, mucosal overexpression of LCN2 in deep remission suggests its potential as a candidate for molecular inflammation warranting further investigation.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Immunology
Masaya Yokoyama, Motoko Y. Kimura, Toshihiro Ito, Koji Hayashizaki, Yukihiro Endo, Yangsong Wang, Ryoji Yagi, Tomoo Nakagawa, Naoya Kato, Hisahiro Matsubara, Toshinori Nakayama
Summary: This study found that Myl9/12 were highly expressed in patients with inflammatory bowel disease and mice with DSS-induced colitis. Administration of anti-Myl9/12 Ab alleviated inflammation and prolonged survival, indicating Myl9/12 may be a new therapeutic target for patients with IBD.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Dora Grgic, Karlo Golubic, Marko Brinar, Zeljko Krznaric
Summary: Faecal calprotectin is an independent predictor of remission in ulcerative colitis patients, with C-reactive protein also playing a role in prediction. The study results indicate that an increase in faecal calprotectin concentration is associated with a decrease in the probability of disease remission.
ANNALS OF MEDICINE
(2022)
Review
Medicine, General & Internal
Guanglin Cui, Qingbo Fan, Zhenfeng Li, Rasmus Goll, Jon Florholmen
Summary: This review discusses the use of TNF antibodies in treating IBD and the evaluation of therapeutic efficacy using current and novel biomarkers. It emphasizes the urgent need for validation and comparison studies of promising novel biomarkers to improve their value in clinical practice.
Article
Pharmacology & Pharmacy
Sara Salvador-Martin, Bartosz Kaczmarczyk, Rebeca Alvarez, Victor Manuel Navas-Lopez, Carmen Gallego-Fernandez, Ana Moreno-Alvarez, Alfonso Solar-Boga, Cesar Sanchez, Mar Tolin, Marta Velasco, Rosana Munoz-Codoceo, Alejandro Rodriguez-Martinez, Concepcion A. Vayo, Ferran Bossacoma, Gemma Pujol-Muncunill, Maria J. Fobelo, Antonio Millan-Jimenez, Lorena Magallares, Eva Martinez-Ojinaga, Ines Loverdos, Francisco J. Eizaguirre, Jose A. Blanca-Garcia, Susana Clemente, Ruth Garcia-Romero, Vicente Merino-Bohorquez, Rafael Gonzalez de Caldas, Enrique Vazquez, Ana Dopazo, Maria Sanjurjo-Saez, Luis A. Lopez-Fernandez
Summary: This study identified overexpression of FCGR1A, FCGR1B, and GBP1 genes as potential pharmacogenomic markers of early response to anti-TNF agents in pediatric IBD patients.
Article
Gastroenterology & Hepatology
Matthias Zilbauer, Robert Heuschkel
Summary: Inflammatory bowel diseases like Crohn's disease and ulcerative colitis are complex conditions that require personalized treatment approaches. Developing biomarkers to predict disease course and treatment response is challenging.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Gastroenterology & Hepatology
Archana Shubhakar, Bas C. Jansen, Alex T. Adams, Karli R. Reiding, Nicholas T. Ventham, Rahul Kalla, Daniel Bergemalm, Paulina A. Urbanowicz, Richard A. Gardner, Manfred IBD BIOM Consortium, Manfred Wuhrer, Jonas Halfvarson, Jack Satsangi, Daryl L. Fernandes, Daniel I. R. Spencer
Summary: This study investigated a composite serum N-glycomic biomarker to predict future disease course in newly diagnosed IBD patients. The biomarker showed a predictive capacity for treatment escalation in both the discovery and replication cohorts of patients.
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Biochemistry & Molecular Biology
Vishal Khatri, Ramaswamy Kalyanasundaram
Summary: This review focuses on the association between IBD and gut inflammasome, as well as recent advances in research and therapeutic strategies for IBD, discussing inflammasomes and their components, outcomes from experimental animals and human studies, inflammasome inhibitors, and developments in inflammasome-targeted therapies for IBD.
Review
Biochemistry & Molecular Biology
HyunTaek Jung, Jae Seok Kim, Keum Hwa Lee, Kalthoum Tizaoui, Salvatore Terrazzino, Sarah Cargnin, Lee Smith, Ai Koyanagi, Louis Jacob, Han Li, Sung Hwi Hong, Dong Keon Yon, Seung Won Lee, Min Seo Kim, Paul Wasuwanich, Wikrom Karnsakul, Jae Il Shin, Andreas Kronbichler
Summary: Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract that mainly affects young people. Recent studies have shown that microRNAs (miRNAs) play an important role in the pathogenesis, diagnosis, and treatment of IBD.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Isidora Simovic, Ida Hilmi, Ruey Terng Ng, Kee Seang Chew, Shin Yee Wong, Way Seah Lee, Stephen Riordan, Natalia Castano-Rodriguez
Summary: ATG16L1 rs2241880 is significantly associated with susceptibility to Crohn's disease (CD) and influences clinical outcomes, especially in Caucasian populations.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2023)
Article
Gastroenterology & Hepatology
Uma Mahadevan, Millie D. Long, Sunanda Kane, Abhik Roy, Marla C. Dubinsky, Bruce E. Sands, Russell D. Cohen, Christina D. Chambers, William J. Sandborn
Summary: The study found that exposure to biologic, thiopurine, or combination therapy during pregnancy did not increase adverse maternal or fetal outcomes, and these treatments can be continued throughout pregnancy for women with IBD to maintain disease control.
Review
Medicine, General & Internal
Blake O. Langley, Sara E. Guedry, Joshua Z. Goldenberg, Douglas A. Hanes, Jennifer A. Beardsley, Jennifer Joan Ryan
Summary: NLR may have utility for clinical and endoscopic disease activity differentiation and prediction of loss of response to infliximab (IFX). Overall findings suggest NLR may be a promising IBD biomarker. Assessment of NLR is non-invasive, low cost, and widely accessible given NLR is easily calculated from blood count data routinely and serially monitored in patients with IBD.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Silvia Salvatori, Francesco Baldassarre, Michelangela Mossa, Giovanni Monteleone
Summary: Long COVID is common in patients with inflammatory bowel diseases (IBD), with fatigue being the most frequent symptom. It does not influence the frequency of IBD relapses, but is more prevalent in female patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Gastroenterology & Hepatology
Thomas M. Goodsall, Tran M. Nguyen, Claire E. Parker, Christopher Ma, Jane M. Andrews, Vipul Jairath, Robert Bryant
Summary: The study systematically identified ultrasound scoring indices for assessing inflammatory bowel disease activity, with common components including bowel wall thickness, colour Doppler imaging, and bowel wall stratification. The correlation between ultrasound indices and reference standards, as well as sensitivity, specificity, accuracy, and other properties, varied within certain ranges. However, reliability and responsiveness data were limited, and most studies were rated with unclear or high risk of bias.
JOURNAL OF CROHNS & COLITIS
(2021)
